| Project/Area Number |
25850086
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Food science
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
TSUDUKI Tsuyoshi 東北大学, (連合)農学研究科(研究院), 准教授 (00404848)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 血管新生 / リノレン酸 / エレオステアリン酸 / 共役リノレン酸 / 共役リノール酸 / キリ / ニガウリ / がん / 共役脂肪酸 / 脂肪酸 / マウス / 血管内皮細胞 / 共役EPA / 共役DHA |
|---|
| Outline of Final Research Achievements |
In the current study, the antiangiogenic effects of ESA were investigated in vitro. ESA also inhibited the formation of capillary-like networks by human umbilical vein endothelial cells (HUVEC) and moderately inhibited HUVEC proliferation and migration in a dose-dependent manner. The mechanism by which ESA inhibited angiogenesis was through activation of peroxisome proliferator-activated receptor (PPAR) γ and induction of apoptosis in HUVEC. We thus demonstrated that, like troglitazone, ESA is a PPARγ ligand, and that it activates PPARγ induces apoptosis in HUVEC, and inhibits angiogenesis. Our findings suggest that ESA has potential use as a therapeutic dietary supplement and medicine for minimizing tumor angiogenesis.
|
